Back to Search
ROGELIO CRUZ, M.D.
M.D.
Hospitalist Physician
NPI: 1629411954IndividualAccepts Medicare
Specialties, Licenses & Credentials
Education
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Class of 2013
Research & Publications (20)
CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
PMID 18067019·Leuk Lymphoma·2007
8-other
Electrical conductivity and stability of concentrated aqueous alumina suspensions.
PMID 15897074·J Colloid Interface Sci·2005
8-other
Regional blood flow distribution and oxygen metabolism during mesenteric ischemia and congestion.
PMID 19285689·J Surg Res·2010
4-observational
Small volume resuscitation with 3% hypertonic saline solution decrease inflammatory response and attenuates end organ damage after controlled hemorrhagic shock.
PMID 19520355·Am J Surg·2009
7-preclinical
Low hematocrit levels increase intracranial pressure in an animal model of cryogenic brain injury.
PMID 19276744·J Trauma·2009
7-preclinical
Retinoic acid modulates retinaldehyde dehydrogenase 1 gene expression through the induction of GADD153-C/EBPbeta interaction.
PMID 18992716·Biochem Pharmacol·2009
7-preclinical
[Malaria and hematological aspects among residents to be impacted by reservoirs for the Santo Antônio and Jirau Hydroelectric Power Stations, Rondônia State, Brazil].
PMID 19578569·Cad Saude Publica·2009
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 3 locations total
- Address
- 550 1ST AVE # TH-1803
NEW YORK, NY 10016 - Phone
- (212) 263-2868
Quick Facts
- NPI
- 1629411954
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 3
- Years in Practice
- 13
- Publications
- 20
Are you this provider?
Claim Your Profile